Effect of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease

Effect of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease(NN9535-4533) - STRIDE

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031200141

Enrollment

800

Registered

2020-10-09

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes with PAD

Interventions

Trial product: Semaglutide administered subcutaneously once-weekly Trial product: Placebo administered subcutaneously once-weekly Treatment period:52 weeks including 8-week dose escalation period

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Male or female, age above or equal to 18 years at the time of informed consent (above or equal to 20 years for Japan) -Diagnosed with type 2 diabetes -Symptomatic PAD with intermittent claudication in Fontaine stage IIa

Exclusion criteria

Exclusion criteria: -Treatment with GLP-1receptor agonist or DPP4 inhibitor -Walking ability limited by condition other than PAD -Planned orthopaedic surgery or other major surgery -Vascular revascularisation procedure 180 days prior to screening or planned

Design outcomes

Primary

Measure	Time frame
Treatment ratio of the median ratio to baseline at week 52 in maximum walking distance	—

Countries

Austria, Belgium, Canada, China, Czech Republic, Denmark, Germany, Hungary, India, Japan, Malaysia, Norway, Poland, Spain, Sweden, Taiwan, United States

Contacts

Public ContactYasumoto Higo

Novo Nordisk Pharma Ltd.

JPHC_clinical_trials@novonordisk.com+81-3-6266-1000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026